Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades

Hagop M Kantarjian; Nicholas J Short; Amir T Fathi; Guido Marcucci; Farhad Ravandi; Martin Tallman; Eunice S Wang; Andrew H Wei

doi:10.1016/j.clml.2021.05.016

Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades

Clin Lymphoma Myeloma Leuk. 2021 Sep;21(9):580-597. doi: 10.1016/j.clml.2021.05.016. Epub 2021 May 29.

Authors

Hagop M Kantarjian¹, Nicholas J Short², Amir T Fathi³, Guido Marcucci⁴, Farhad Ravandi², Martin Tallman⁵, Eunice S Wang⁶, Andrew H Wei⁷

Affiliations

¹ Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: hkantarjian@mdanderson.org.
² Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA.
³ Leukemia Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Gehr Family Center for Leukemia Research City of Hope, Duarte, CA, USA.
⁵ Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
⁶ Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
⁷ Department of Clinical Hematology, The Alfred Hospital and Monash University, Melbourne, Australia.

PMID: 34176779
DOI: 10.1016/j.clml.2021.05.016

Abstract

With the Food and Drug Administration approval of 9 agents for different acute myeloid leukemia (AML) indications, the prognosis and management of AML is evolving rapidly. Herein, we review the important milestones in the history of AML research and therapy, discuss insights regarding prognostic assessment and prediction of treatment outcome, detail practical supportive care measures, and summarize the current treatment landscape and areas of evolving research.

Keywords: AML; Biology; Prognosis; Targeted therapy; Therapy.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Aged
Female
Humans
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Prognosis
Time Factors
Treatment Outcome

Grants and funding

P30 CA016672/CA/NCI NIH HHS/United States